Research graph

References

References from A 52‐Week Efficacy and Safety Study of Teneligliptin, as an Add‐On to Empagliflozin and Metformin in Patients With Type 2 Diabetes Mellitus: A Randomised, Double‐Blind, Placebo‐Controlled Phase 3 Trial ( <scp>TERA305</scp> Study). Local targets link to admitted publications; unresolved targets remain external evidence.

Unresolved reference

2025 · External reference

10.4093/dmj.2024.0818

10.4093/dmj.2024.0818 · External reference

10.1007/s13300‐018‐0493‐2

10.1007/s13300‐018‐0493‐2 · External reference

10.1111/dom.12417

10.1111/dom.12417 · External reference

10.2337/dc14‐2517

10.2337/dc14‐2517 · External reference

10.1080/17425255.2016.1215427

10.1080/17425255.2016.1215427 · External reference

10.3803/enm.2023.1688

10.3803/enm.2023.1688 · External reference

10.4093/dmj.2022.0387

10.4093/dmj.2022.0387 · External reference

10.1111/dom.12814

10.1111/dom.12814 · External reference

10.2337/dc15‐0811

10.2337/dc15‐0811 · External reference

10.1111/dom.12741

10.1111/dom.12741 · External reference

10.2337/dc26‐s009

10.2337/dc26‐s009 · External reference

10.1111/dom.16550

10.1111/dom.16550 · External reference

10.1007/s00125‐012‐2827‐3

10.1007/s00125‐012‐2827‐3 · External reference

10.1358/dot.2013.49.10.2035882

10.1358/dot.2013.49.10.2035882 · External reference

10.1002/cpdd.29

10.1002/cpdd.29 · External reference

10.4093/dmj.2021.0016

10.4093/dmj.2021.0016 · External reference

10.1111/dom.13566

10.1111/dom.13566 · External reference

10.1111/dom.12631

10.1111/dom.12631 · External reference

10.1111/dom.12424

10.1111/dom.12424 · External reference

10.4093/dmj.2025.0469

10.4093/dmj.2025.0469 · External reference

10.1016/j.diabres.2026.113272

10.1016/j.diabres.2026.113272 · External reference

10.1016/j.freeradbiomed.2020.07.030

10.1016/j.freeradbiomed.2020.07.030 · External reference

10.1007/s13300‐021‐01148‐1

10.1007/s13300‐021‐01148‐1 · External reference

10.4093/dmj.2025.0710

10.4093/dmj.2025.0710 · External reference